menu
    • menu
    [{"orgOrder":0,"company":"Syneos Health","sponsor":"Eloxx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"ELX-02","moa":"80S Ribosome","graph1":"Nephrology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Acorda Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tizanidine Hydrochloride","moa":"Adrenergic receptor alpha-2","graph1":"Neurology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"5-grass Mix Allergen Extract","moa":"Allergen cell","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Clarus Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Hormone","year":"2016","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"Androgen Receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EMA401","moa":"Angiotensin II type 2 (AT-2) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"EMA401","moa":"Angiotensin II type 2 (AT-2) receptor","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"SRT-015","moa":"ASK1","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Enzyme","year":"2017","type":"Inapplicable","leadProduct":"Asparaginase","moa":"Asparagine","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"AZD0156","moa":"ATM serine\/threonine kinase (ATM)","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Philogen","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"Bifikafusp Alfa","moa":"BCMA receptor\/Microtubule","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kedrion","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Protein","year":"2012","type":"Inapplicable","leadProduct":"Albumin","moa":"Bilirubin","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Perflutren","moa":"blood substitutes and\/or diagnostics (perfluorochemicals)","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Prism Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"INDIA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"PRI-724","moa":"CBP\/beta catenin","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2024","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"GERMANY","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"BT595","moa":"CD20","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"ALXN1820","moa":"Complement factor P (CFP)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"Cyclooxygenase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Aspirin","moa":"Prostaglandin G\/H synthase 1; 3-hydroxy-3-methylglutaryl-coenzyme A reductase; Prostaglandin G\/H synthase 2; Aldo-keto reductase family 1 member C1; 5'-AMP-activated protein kinase; Endothelin-1 receptor; Cellular tumor antigen p53; Endoplasmic reticulum chaperone BiP; Ribosomal protein S6 kinase alpha-3; NF-kappa-B inhibitor alpha; Tumor necrosis factor-inducible gene 6 protein; Caspase-1; Caspase-3; Inhibitor of nuclear factor kappa-B kinase subunit beta; Extracellular signal-regulated kinase (ERK); G1\/S-specific cyclin-D1; Myc proto-oncogene protein; Proliferating cell nuclear antigen; Cyclin A; Sialidase-1","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Antares Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Abiraterone Acetate","moa":"Cytochrome P450 17A1","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Antares Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Antares Pharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Royal DSM","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"NETHERLANDS","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"DHA","moa":"DHA level","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Galera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"GC4711","moa":"Dismutase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Appili Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Plant Extract\/Herbal","year":"2017","type":"Inapplicable","leadProduct":"Metronidazole","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"MGB Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"medac","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Treosulfan","moa":"DNA","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Byondis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"Trastuzumab Duocarmazine","moa":"DNA | Receptor protein-tyrosine kinase erbB-2","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"enzyme inhibitors: inhibitors of histone deacetylase; vinca alkaloids","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Estetrol","moa":"Estrogen receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Swedish Orphan Biovitrum AB","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"SWEDEN","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Efanesoctocog Alfa","moa":"F8*","graph1":"Genetic Disease","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Recordati Rare Diseases","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Udonitrectag","moa":"FGFR4","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"On Target Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Pafolacianine","moa":"Folate-alpha receptor||FOLR","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Crossject","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Agreement","leadProduct":"Midazolam","moa":"GABA-A receptor; anion channel","graph1":"Neurology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Crossject","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Crossject"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kashiv BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Protein","year":"2017","type":"Inapplicable","leadProduct":"Pegfilgrastim","moa":"Granulocyte colony stimulating factor receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"DENMARK","productType":"Hormone","year":"2017","type":"Inapplicable","leadProduct":"Dasiglucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Bausch & Lomb Incorporated","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"CANADA","productType":"Steroid","year":"2013","type":"Inapplicable","leadProduct":"Loteprednol Etabonate","moa":"Glucocorticoid receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Enteris Biopharma Inc","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Leuprolide Acetate","moa":"Gonadotropin-releasing hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Seres Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Microorganism","year":"2015","type":"Inapplicable","leadProduct":"SER-109","moa":"Gut microbiome","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Givinostat HCl","moa":"HDAC","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"CANADA","productType":"Peptide, Unconjugated","year":"2013","type":"Inapplicable","leadProduct":"Plecanatide","moa":"Heat-stable enterotoxin receptor","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Lantheus Medical Imaging","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Perflutren","moa":"Homeostasis","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Debiopharm","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Debio 0932","moa":"HSP90","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ViiV Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"GSK3640254","moa":"Human immunodeficiency virus Maturation (HIV Mat)","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Omalizumab","moa":"Ig epsilon chain C region","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ CuraTeQ Biologics","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ CuraTeQ Biologics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"ALXN1830","moa":"IgG receptor FcRn large subunit p51","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Siltuximab","moa":"Interleukin-6","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Tocilizumab","moa":"Interleukin-6 receptor alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Iodixanol","moa":"iodine-containing contrast media","graph1":"Nephrology","graph2":"Phase IV","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"11","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Shanghai SIMR Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SR419","moa":"Ion Channel","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Abcuro, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"ABC008","moa":"Killer cell lectin-like receptor subfamily G member 1 (KLRG1)","graph1":"Immunology","graph2":"Phase II\/ Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Mereo BioPharma Group","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Alvelestat","moa":"Leukocyte elastase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"MetrioPharm","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"MP1032","moa":"Macrophage","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Neurim Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Piromelatine","moa":"Melatonin receptor","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"9","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Asieris Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"APL-1202","moa":"MetAP2","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Asieris Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Asieris Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Bevenopran","moa":"Mu opioid receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Relmada Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Methadone","moa":"Mu opioid receptor||N-methyl-D-aspartate receptor (NMDAR)","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Vyluma","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"NVK-002","moa":"Muscarinic receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"Purified Protein Derivative","moa":"Mycobacterial protein","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"EVP-6124","moa":"Neuronal acetylcholine receptor protein alpha-7 subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aptinyx","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"NYX-2925","moa":"N-methyl-D-aspartate receptor (NMDAR)","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Innate Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"MIS416","moa":"NOD2\/TLR9","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"ALO-02","moa":"Opioid receptor (OPR)","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Trevi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Controlled Substance","year":"2019","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Trevi Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Nalbuphine Hydrochloride","moa":"Opioid receptors; mu\/kappa\/delta","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Collaboration","leadProduct":"Daridorexant","moa":"Orexin receptor","graph1":"Sleep","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Idorsia Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"U.S.A","productType":"Controlled Substance","year":"2022","type":"Partnership","leadProduct":"Daridorexant HCl","moa":"Orexin receptor 1 | Orexin receptor 2","graph1":"Sleep","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Syneos Health \/ Idorsia Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Idorsia Pharmaceuticals"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ARGENTINA","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"Programmed cell death protein 1","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Holy Stone Healthcare","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TAIWAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mesalazine","moa":"Peroxisome proliferator-activated receptor gamma | Cyclooxygenase | Arachidonate 5-lipoxygenase","graph1":"Immunology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Dietary Supplement","year":"2019","type":"Inapplicable","leadProduct":"Patiromer","moa":"Potassium","graph1":"Nephrology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Odyssey Health","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Steroid","year":"2023","type":"Agreement","leadProduct":"PRV-002","moa":"Pregnane X receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Spray","sponsorNew":"Syneos Health \/ Odyssey Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Odyssey Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Synermore Biologics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"SYN023","moa":"Rabies virus glycoprotein","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Collaboration","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Daiichi Sankyo","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Daiichi Sankyo"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Daxibotulinumtoxin A","moa":"SNAP25","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Galera Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Avasopasem manganese","moa":"SOD","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DSP-0337","moa":"STAT3","graph1":"Oncology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Revance Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Daxibotulinumtoxina","moa":"Synaptosomal nerve-associated protein 25 (SNAP-25)","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Oncolys BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"OBP-301","moa":"Telomerase reverse transcriptase (TERT)","graph1":"Oncology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Oncolys BioPharma","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Oncolys BioPharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"FivepHusion","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sumitomo Pharma America","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"DSP-0509","moa":"TLR7","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Tuberculin PPD","moa":"Toll-like receptor 2","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"JHP Pharmaceuticals LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"Aplisol","moa":"Tuberculin PPD","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"162","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"ACH-000029","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Otsuka Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Otsuka Pharmaceutical"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Aiolos Bio","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AIO-001","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Syneos Health \/ Aiolos Bio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Aiolos Bio"},{"orgOrder":0,"company":"Syneos Health","sponsor":"AprilBio","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"APB-R3","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Syneos Health \/ AprilBio","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ AprilBio"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"UNITED KINGDOM","productType":"Protein","year":"2013","type":"Inapplicable","leadProduct":"Cat-Pad","moa":"Undisclosed","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Creative Medical Technology","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Partnership","leadProduct":"CELZ-201","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase I\/ Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Creative Medical Technology","highestDevelopmentStatusID":"7","companyTruncated":"Syneos Health \/ Creative Medical Technology"},{"orgOrder":0,"company":"Syneos Health","sponsor":"US Specialty Formulations, LLC","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"CoV2-OGEN1","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Syneos Health \/ US Specialty Formulations, LLC","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ US Specialty Formulations, LLC"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"NETHERLANDS","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"GATT-Patch","moa":"Undisclosed","graph1":"Hematology","graph2":"Undisclosed","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Patch","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"1","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"GeneScience Pharmaceuticals Co Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GS1-144","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Medicago","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"H5 VLP","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Hydrogel","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Himuka AM Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"HM201","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Himuka AM Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Himuka AM Pharma"},{"orgOrder":0,"company":"Syneos Health","sponsor":"ALK","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"DENMARK","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Stallergenes Greer","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"House Dust Mite Allergen Extract","moa":"Undisclosed","graph1":"Immunology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"Levocept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Shanghai Novamab Biopharmaceuticals Co. Ltd.","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"LQ036","moa":"Undisclosed","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Shanghai Novamab Biopharmaceuticals Co. Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Shanghai Novamab Biopharmaceuticals Co. Ltd."},{"orgOrder":0,"company":"Syneos Health","sponsor":"Liminal BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"PBI-4547","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Que Oncology","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"AUSTRALIA","productType":"Undisclosed","year":"2018","type":"Inapplicable","leadProduct":"Q-122","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Chengdu Kanghua Biological Products","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Inapplicable","leadProduct":"Recombinant Norovirus Hexavalent Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Chengdu Kanghua Biological Products","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Chengdu Kanghua Biological Products"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"FRANCE","productType":"Undisclosed","year":"2012","type":"Inapplicable","leadProduct":"RPh201","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SB206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Novan","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"SB206","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"F-star Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"SB9200","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ F-star Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ F-star Therapeutics"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CANADA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"SLC-391","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"SynerK Pharmatech (Suzhou) Limited","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"SNK-396","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ SynerK Pharmatech (Suzhou) Limited","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ SynerK Pharmatech (Suzhou) Limited"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"SOV2012-F1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"SOV2012-F1","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Undisclosed","year":"2014","type":"Inapplicable","leadProduct":"SUN13837","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Tsumura & Co","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"JAPAN","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"TU-100","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"ISRAEL","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"TV-46763","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"VB0004","moa":"Undisclosed","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Syneos Health \/ Undisclosed"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Veracept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Sebela Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Veracept","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Insert","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Otsuka Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"JAPAN","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tolvaptan","moa":"Vasopressin V2 receptor","graph1":"Nephrology","graph2":"Approved FDF","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"15","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Daiichi Sankyo","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"JAPAN","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"DS-5565","moa":"Voltage-gated calcium channel alpha2\/delta subunit 1 | Voltage-gated calcium channel alpha2\/delta subunit 2","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Kamada","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"10","companyTruncated":"Syneos Health \/ Syneos Health"},{"orgOrder":0,"company":"Syneos Health","sponsor":"Cryoport Systems Inc","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Syneos Health","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syneos Health \/ Syneos Health","highestDevelopmentStatusID":"3","companyTruncated":"Syneos Health \/ Syneos Health"}]

    Find Clinical Drug Pipeline Developments & Deals by Syneos Health

    Menu

    Syneos Health

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants Wit...

                            Details : Leronlimab is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 21, 2024

                            Lead Product(s) : Leronlimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : CytoDyn

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : APL-1202

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunt...

                            Details : APL-1202 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 30, 2024

                            Lead Product(s) : APL-1202

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Asieris Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GS1-144

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase I

                            Recipient : GeneScience Pharmaceuticals Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

                            Details : GS1-144 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hot Flashes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            January 12, 2024

                            Lead Product(s) : GS1-144

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase I

                            Recipient : GeneScience Pharmaceuticals Co Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Midazolam

                            Therapeutic Area : Neurology

                            Study Phase : Approved FDF

                            Sponsor : Crossject

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

                            Details : Under the agreement, Syneos Health will provide support in all pre-launch and launch activities for Zepizure (midazolam), an epileptic rescue therapy for epileptic seizures.

                            Product Name : Zepizure

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            January 04, 2024

                            Lead Product(s) : Midazolam

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved FDF

                            Sponsor : Crossject

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AIO-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Study Phase : Phase I

                            Sponsor : Aiolos Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Evaluate the AIO-001 in Healthy Participants

                            Details : AIO-001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Respiratory Tract Diseases.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : AIO-001

                            Therapeutic Area : Pulmonary/Respiratory Diseases

                            Highest Development Status : Phase I

                            Sponsor : Aiolos Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRV-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Odyssey Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Odyssey Health, Inc, Selects Syneos Health to Support Investigational New Drug Application for Treatment of Co...

                            Details : ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of moderate traumatic brain injury. It crosses BBB & activates gene response leading to the production of proteins that reduce inflammation, oxidative str...

                            Product Name : Undisclosed

                            Product Type : Steroid

                            Upfront Cash : Undisclosed

                            November 16, 2023

                            Lead Product(s) : PRV-002

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Odyssey Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Givinostat HCl

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : The Italfarmaco Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Italfarmaco Group Completes FDA Submission of New Drug Application for Givinostat in Duchenne Muscular Dystrop...

                            Details : ITF2357 (givinostat) is an investigational drug act as a inhibits histone deacetylases (HDACs), which is investigated for the treatment of Duchenne Muscular Dystrophy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2023

                            Lead Product(s) : Givinostat HCl

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : The Italfarmaco Group

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SNK-396

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : SynerK Pharmatech (Suzhou) Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol

                            Details : SNK-396 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hypercholesterolemia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 09, 2023

                            Lead Product(s) : SNK-396

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : SynerK Pharmatech (Suzhou) Limited

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : FivepHusion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health

                            Details : The collaboration is for strategically and optimally progress development and commercialization of FivepHusion's enhanced chemotherapeutic formulation Deflexifol, an anti-cancer drug reformulation combining 5-fluorouracil and its biomodulator leucovorin,...

                            Product Name : Deflexifol

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Undisclosed

                            May 26, 2023

                            Lead Product(s) : Fluorouracil,Calcium Folinate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : FivepHusion

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Syneos Health

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Efanesoctocog Alfa

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Recipient : Swedish Orphan Biovitrum AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated...

                            Details : Efanesoctocog Alfa is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 18, 2023

                            Lead Product(s) : Efanesoctocog Alfa

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Recipient : Swedish Orphan Biovitrum AB

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth